leqembi

Medicare Will Pay For A Common Alzheimer’s Test But It May Not Be Reliable

Last year, Medicare decided it would routinely pay for sophisticated imaging tests for Alzheimer’s disease called amyloid-PET (positron emission tomography) scans. The move will make it easier for people with early-stage memory loss to get tested and potentially become eligible for a class of new drugs that aim to slow the progression of Alzheimer’s. However, many neuroscientists and imaging experts [...]

By |2024-01-09T15:09:53-05:00January 9th, 2024|dementia|0 Comments

Should People With No Symptoms Get A Diagnosis of Alzheimer’s Disease?

The National Institute on Aging and the Alzheimer’s Association have proposed revised clinical guidelines that would designate seven major stages of the brain disease. The first two would be for people who have no symptoms but may be at higher risk for Alzheimer’s. These technical guidelines, which would update a 2018 version, could have enormous, and conflicting, implications for drug [...]

By |2023-08-08T10:47:15-04:00August 8th, 2023|dementia|0 Comments

FDA Has Approved The Anti-Alzheimer’s Drug Leqembi. What You Need To Know

The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer’s drug lecanamab, marked as Leqembi by drugmakers Eisai and Biogen. Here is what you need to know: What does it do? In a formal phase 3 trial, Leqembi was shown to slow the progression of memory loss and cognitive impairment in patients with early-stage Alzheimer’s disease by [...]

By |2023-07-06T17:25:34-04:00July 6th, 2023|dementia, Uncategorized|0 Comments

The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules

The drug industry and its supporters are blasting the Centers for Medicare and Medicaid Services (CMS) for proposing to limit Medicare payments for the new anti-Alzheimer’s drug lecanemab to patients who participate in a trial or a special registry aimed at tracking their experience with the drug. CMS says the record-keeping will help provide important, real-world information about the benefits [...]

By |2023-06-14T12:12:06-04:00June 14th, 2023|dementia|0 Comments

The War Over Whether Medicare Should Pay For New Anti-Alzheimer’s Drugs

The powerful Alzheimer’s Disease lobby is fighting a multi-billion-dollar battle on two fronts. It is quietly trying to limit restrictions the Food and Drug Administration puts on the use of new drugs aimed at slowing the progression of the brain disease. And it is publicly pressing Medicare to pay for the widespread use of the monoclonal antibodies FDA already has [...]

By |2023-05-17T15:27:50-04:00May 17th, 2023|dementia|0 Comments

Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi

Medical experts are raising new questions about the safety of the anti-Alzheimer’s drug lecanemab, which is marketed as Leqembi by drugmakers Biogen and Eisai. One study, which looked in detail at the death of a participant in a Leqembi research trial, suggests that people with a condition that affects as many as half of those with Alzheimer’s Disease may be [...]

By |2023-04-25T10:22:43-04:00April 25th, 2023|dementia|0 Comments

The FDA Approved The New Anti-Alzheimer’s Drug Leqembi. What You Need To Know

The FDA’s decision to grant accelerated approval for the anti-Alzheimer’s drug lecanemab, which will be sold as Leqembi, has significant potential for research into treatment of the disease. But people living with Alzheimer’s and their families will face difficult choices once the drug is made available later this month by Biogen and the Japanese firm Eisai. A trial found the [...]

By |2023-01-09T09:58:28-05:00January 9th, 2023|dementia, Uncategorized|0 Comments